Cempra, Inc.
http://www.cempra.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cempra, Inc.
Chinese Oncology Startups Scoop Up VC/PE Deals In December
Oncology-focused Innovo, CytosinLab, Sino-Cell and Sinogen announced closings of early-stage funding rounds worth up to $14m. Meanwhile, Chinese developers of therapies for asthma, autoimmune skin disorders and rare diseases also raised similar new funds.
US FDA Rejects Melinta Effort To Go Beyond Court Order In FedEx-Driven ANDA Dispute
Court found FDA erred in finding Melinta received notice of Paragraph IV certification for generic Minocin on date specified by Nexus. Agency will not require Nexus to send a new notice or give Melinta heads up of final approval of the ANDA.
Pharma’s Digital Pathology Build-Out; Part 2 – What It Means
Both providers and users of digital pathology are confident that clinical use cases and the evidence needed to assure payers and encourage investment by commercial labs will overcome challenges around access and adoption.
Pharma’s Digital Pathology Build-Out; Part 1 – The State Of Play
Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
-
- Cempra Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice